EAS 2017 Congress Prague highlights

      EAS Congress Prague, held during 23–26 April 2017, broke all previous records with almost 2500 delegates attending this premier event. The Congress featured topical ‘state-of-the-art’ plenaries, novel therapeutic approaches in managing elevated cholesterol and triglycerides, as well as insights into how genetics impacts dietary approaches for preventing cardiometabolic disease. Here we provide a snapshot of some of the highlights.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Murphy A.J.
        • Tall A.R.
        Disordered haematopoiesis and athero-thrombosis.
        Eur. Heart J. 2016; 37: 1113-1121
        • Tall A.R.
        • Levine R.L.
        Cardiovascular disease: commonality with cancer.
        Nature. 2017; 543: 45-47
        • Hill A.B.
        The environment and disease. Association or causation?.
        Proc. R. Soc. Med. 1965; 58: 295-300
        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • et al.
        Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society.
        Eur. Heart J. 2013; 34: 3478-3490
        • Ference B.A.
        • Ginsberg H.N.
        • Graham I.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur. Heart J. 2017 Apr 24; ([Epub ahead of print])
        • Yusuf S.
        • Hawken S.
        • Ounpuu S.
        • et al.
        Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
        Lancet. 2004; 364: 937-952
        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N. Engl. J. Med. 2017; 376: 1713-1722
        • Ridker P.M.
        • Revkin J.
        • Amarenco P.
        • et al.
        Cardiovascular efficacy and safety of bococizumab in high-risk patients.
        N. Engl. J. Med. 2017; 376: 1527-1539
        • Wiegman A.
        • Gidding S.S.
        • Watts G.F.
        • et al.
        Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
        Eur. Heart J. 2015; 36: 2425-2437
        • Nicholls S.J.
        • Puri R.
        • Anderson T.
        • et al.
        Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.
        JAMA. 2016; 316: 2373-2384
        • Giugliano R.P.
        • Wiviott S.D.
        • Blazing M.A.
        • et al.
        Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : a prespecified analysis of the IMPROVE-IT trial.
        JAMA Cardiol. 2017 Mar 14; ([Epub ahead of print])
        • Descamps O.S.
        • Bruniaux M.
        • Guilmot P.F.
        • Tonglet R.
        • Heller F.R.
        Lipoprotein concentrations in newborns are associated with allelic variations in their mothers.
        Atherosclerosis. 2004; 172: 287-298
        • Dietschy J.M.
        • Turley S.D.
        Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal.
        J. Lipid Res. 2004; 45: 1375-1397
        • Gaudet D.
        • Digenio A.
        • Alexander V.
        • et al.
        The APPROACH study: a randomized, double-blind, placebo-controlled, Phase 3 study of volvanesorsen administered subcutaneously to patients with familial chylomicronaemia syndrome (FCS).
        Atherosclerosis. 2017; (in press)
        • Gaudet D.
        • Gipe D.
        • Hovingh G.K.
        • et al.
        Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolaemia; a single arm, open-label, proof of concept study.
        Atherosclerosis. 2016; 252: e254-e255
        • Bray M.S.
        • Loos R.J.
        • McCaffery J.M.
        • et al.
        NIH working group report-using genomic information to guide weight management: from universal to precision treatment.
        Obesity. 2016; 24: 14-22
        • Wang T.
        • Huang T.
        • Zheng Y.
        • et al.
        Genetic variation of fasting glucose and changes in glycemia in response to 2-year weight-loss diet intervention: the POUNDS LOST trial.
        Int. J. Obes. (Lond). 2016; 40: 1164-1169